DESTINY PHARMA PLC

BN1 9SB (South East)

Start Date End Date Funded Value Relevance

CSV

25 50 100

£801,493

Sep 20 - Oct 22

SPOR-COV: Prophylaxis of COVID-19 using Innate Immunity

Innovate UK award to SPOREGEN LIMITED and Simon Cutting

£586,601

Jan 19 - Aug 22

Evaluation of the Novel XF Drugs as Bacterial Resistance Breakers

Innovate UK award to DESTINY PHARMA PLC and Daniel Hynes

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}